DDX0140P-100
antibody from Novus Biologicals
Targeting: CD40LG
CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- DDX0140P-100 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal CD40 Ligand/TNFSF5 Antibody
- Antibody type
- Monoclonal
- Description
- Ion exchange chromatography.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 0.5 mg/ml
- Storage
- Store at -20C. Avoid freeze-thaw cycles.
Submitted references Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo.
Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
Stax AM, Gelderman KA, Kamerling SW, van der Geest R, Schlagwein N, van Kooten C
Journal of immunological methods 2008 Jun 1;335(1-2):46-52
Journal of immunological methods 2008 Jun 1;335(1-2):46-52
Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Mar;7(3):691-703
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Mar;7(3):691-703
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.
Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA
Blood 2001 Aug 15;98(4):1047-54
Blood 2001 Aug 15;98(4):1047-54
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.
Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA
Blood 2001 Aug 15;98(4):1047-54
Blood 2001 Aug 15;98(4):1047-54
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
Sallusto F, Cella M, Danieli C, Lanzavecchia A
The Journal of experimental medicine 1995 Aug 1;182(2):389-400
The Journal of experimental medicine 1995 Aug 1;182(2):389-400
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: CD40 Ligand/TNFSF5 Antibody (LL48) [DDX0140P-100] - FACS staining of hCD40L-transfected L cells with LL48 clone
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Neutralization: CD40 Ligand/TNFSF5 Antibody (LL48) [DDX0140P-100] - Inhibition of IL12 production by CD40L-stimulated human monocyte-derived DCs by LL48 clone (Stax AM et al, 2008, J ImmunolMethods)